Cargando…

Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

BACKGROUND: To evaluate the value of KRAS codon 13 mutations in patients with advanced colorectal cancer (advanced CRC) treated with oxaliplatin and fluoropyrimidines. METHODS: Tumor specimens from 201 patients with advanced CRC from a randomized, phase III trial comparing oxaliplatin/5-FU vs. oxali...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reinacher-Schick, Anke, Schulmann, Karsten, Modest, Dominik P, Bruns, Nina, Graeven, Ulrich, Jaworska, Malgorzata, Greil, Richard, Porschen, Rainer, Arnold, Dirk, Schmiegel, Wolff, Tannapfel, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442969/ https://www.ncbi.nlm.nih.gov/pubmed/22876876 http://dx.doi.org/10.1186/1471-2407-12-349

Ejemplares similares

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
por: Modest, D. P., et al.
Publicado: (2016)

Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials
por: Noepel-Duennebacke, Stefanie, et al.
Publicado: (2021)

Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial
por: Stintzing, Sebastian, et al.
Publicado: (2018)

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
por: Kurreck, A., et al.
Publicado: (2020)

Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer.
por: Petrasch, S., et al.
Publicado: (1998)

Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages
por: Li, Wenbin, et al.
Publicado: (2015)

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
por: Modest, Dominik Paul, et al.
Publicado: (2022)

KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research
por: He, Kang, et al.
Publicado: (2020)

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
por: von Einem, J. C., et al.
Publicado: (2014)

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
por: Stintzing, S, et al.
Publicado: (2019)

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
por: Heinrich, K., et al.
Publicado: (2023)

Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials
por: Wieser, Martina, et al.
Publicado: (2010)

Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
por: Jones, Robert P, et al.
Publicado: (2017)

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
por: Hoehler, T, et al.
Publicado: (2013)

Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing
por: Richman, Susan D., et al.
Publicado: (2011)

Causes of mortality in elderly UICC stage III colon cancer (CC) patients––Tumor‐related death and competing risks from the German AIO colorectal study group Colopredict Plus (CPP) registry
por: Nöpel‐Dünnebacke, Stefanie, et al.
Publicado: (2022)

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group
por: Ettrich, Thomas J., et al.
Publicado: (2018)

Label-free, automated classification of microsatellite status in colorectal cancer by infrared imaging
por: Kallenbach-Thieltges, Angela, et al.
Publicado: (2020)

Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC)
por: Pang, Siew-Wai, et al.
Publicado: (2019)

Personalized treatment for advanced colorectal cancer: KRAS and beyond
por: Patel, Gargi Surendra, et al.
Publicado: (2013)

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
por: Amatu, Alessio, et al.
Publicado: (2022)

Different oncological features of colorectal cancer codon-specific KRAS mutations: Not codon 13 but codon 12 have prognostic value
por: Ahn, Hong-Min, et al.
Publicado: (2023)

Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy
por: Tsubaki, Masanobu, et al.
Publicado: (2023)

Colorectal Adenoma – Resection Techniques and Surveillance
por: Kähler, Georg, et al.
Publicado: (2014)

Geriatric assessment and the variance of treatment recommendations in geriatric patients with gastrointestinal cancer—a study in AIO oncologists
por: Büttelmann, M., et al.
Publicado: (2023)

Immunoscreening of the extracellular proteome of colorectal cancer cells
por: Klein-Scory, Susanne, et al.
Publicado: (2010)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

Brain metastasis in advanced colorectal cancer: results from the South Australian metastatic colorectal cancer (SAmCRC) registry
por: Tapia Rico, Gonzalo, et al.
Publicado: (2017)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

Early diagnosis of colorectal cancer via plasma proteomic analysis of CRC and advanced adenomatous polyp
por: Fayazfar, Setareh, et al.
Publicado: (2019)

Lasting response by vertical inhibition with cetuximab and trametinib in KRAS‐mutated colorectal cancer patient‐derived xenografts
por: Reissig, Timm M., et al.
Publicado: (2023)

Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial
por: Nehls, O, et al.
Publicado: (2002)

Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer
por: Braun, M S, et al.
Publicado: (2003)

Efficacy of Goshajinkigan for Peripheral Neurotoxicity of Oxaliplatin in Patients with Advanced or Recurrent Colorectal Cancer
por: Kono, Toru, et al.
Publicado: (2011)

Association between KRAS mutation and lung metastasis in advanced colorectal cancer
por: Pereira, A A L, et al.
Publicado: (2015)

KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer
por: Radanova, Maria, et al.
Publicado: (2023)

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
por: van de Haar, Joris, et al.
Publicado: (2023)

Recent Advancements and Challenges of AIoT Application in Smart Agriculture: A Review
por: Adli, Hasyiya Karimah, et al.
Publicado: (2023)

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
por: Alig, Annabel H. S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6t23bkq8u4qk053sa2f53839tu